This narrative review looks at how immune checkpoint blockade might be used to treat nasopharyngeal carcinoma. The authors discuss the potential for these therapies to help patients with this specific cancer type. The review notes that while current survival rates for non-metastatic cases are high, new treatments are still needed.
The main challenge identified is that the body can develop resistance to these drugs over time. Without effective biomarkers to predict who will respond, it is difficult to choose the right patients for this therapy. The review does not report specific safety data or adverse events.
Readers should understand that this is a narrative review, not a clinical trial with patient data. The findings are meant to help design future research rather than change current practice. More studies are needed to confirm if these drugs work safely and effectively for this condition.